Eli Lilly (NYSE:LLY) said today that the FDA approved label changes for its once-weekly Trulicity injection. The new label was updated to include use in combination with basal insulin for adults with Type 2 diabetes.
The label update was based on results from a phase IIIb randomized clinical trial, Lilly said, which evaluated Trulicity as an add-on to titrated insulin glargine for 28 weeks. The data showed that the Trulicity-insuline glargine combination significantly lowered A1C compared to a placebo with insulin glargine.
Get the full story at our sister site, Drug Delivery Business News.
The post Eli Lilly wins label expansion for Trulicity injection with basal insulin appeared first on MassDevice.